![]() |
Market Research Report
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019 |
||||||
Published by | Global Markets Direct | Product code | 465217 | ||||
Published | Content info | 135 Pages Delivery time: 1-2 business days |
|||||
Price |
|
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019 | ||
Published: March 29, 2019 | Content info: 135 Pages |
|
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) (Oncology) pipeline landscape.
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics DevelopmentPipeline Overview Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H1 2019
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 1 respectively.
Gorlin Syndrome (Basal Cell Nevus Syndrome Nevoid Basal Cell Carcinoma Syndrome) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.